Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BLMZ
- Development stage
- Phase 3
- Lead developer
- Beijing Chest Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**BLMZ** is a 9-month, all-oral combination regimen for rifampicin-resistant tuberculosis comprising **bedaquiline, linezolid, moxifloxacin, and pyrazinamide**. It combines inhibition of mycobacterial ATP synthase, bacterial protein synthesis, DNA gyrase and topoisomerase IV, and pyrazinamide-mediated antimycobacterial activity after conversion to pyrazinoic acid. Beijing Chest Hospital is evaluating the regimen in the Phase 3 INSPIRE-BLMZ Chinese cohort study in participants aged 12 years and older with rifampicin-resistant tuberculosis. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07268664))
- Other names
- bedaquiline + linezolid + moxifloxacin + pyrazinamideBLMZ regimen
02
Targets
23S rRNA (23S ribosomal RNA)AtpE (ATP synthase subunit c of Mycobacterium tuberculosis)DNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on BLMZ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BLMZ.